• Search Funds
  • Model Portfolios
  • Provider
  • Sector
  • Manager

Search by provider name

Search by sector name

Search by manager name

Search by Risk Level

AXA Framlington Biotech Z INC

  • Fund Info & charges
  • Performance
  • Fund breakdown
  • Dividend History
Fund Provider AXA Investment Managers UK Limited
Fund Summary The aim of this Fund is to provide long-term capital growth.
SEDOL code BRJZVL2
ISIN GB00BRJZVL27
Fund code FMBZI
Managers Linden Thomson, Dani Saurymper
Manager Tenure 7 years
Morningstar Category Sector Equity Biotechnology
IMA Sector Specialist
Fund Size £430 million
Fund Type OEIC
Management Style Active
Total Expense Ratio (TER) 0.82%
Cavendish ongoing charge 0.05%
FundsNetwork Service Fee 0.20%
Minimum Initial Investment £25
Minimum Top Up £25
Minimum Monthly Investment £25
Sell Price £1.175
Buy Price £1.175
Price Change -0.085%
Price Date 16th August 2019
Yield Currently unavailable
Dividend Frequency Semi-Annually
ISA Eligible Yes
SIPP Eligible Yes
Inception Date 26th November 2001
Fund Status OPEN

3-year Mean Monthly Return: 0.758%

Annual Returns 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009
Fund Performance +1.02% +7.80% +27.22% -21.97% +55.28% +32.55% +39.88% +21.92% +23.29% +0.92%
Benchmark Performance
(Sector Equity Biotechnology)
-0.53% +8.45% +28.22% -20.81% +48.65%
Time Period Cumulative Benchmark Performance
(Sector Equity Biotechnology)
Fund Compared to Benchmark
1 day -0.09% -0.48% +0.39%
1 week -3.13% -0.45% -2.69%
1 month -2.33% +0.44% -2.77%
3 months 1.29% -5.05% +6.34%
6 months -2.25% +0.12% -2.37%
1 year -7.19% -2.15% -5.03%
3 years 14.41% +31.77% -17.36%
5 years 60.06% +65.47% -5.41%
10 years 351.74% +372.96% -21.22%
YTD 14.97% +10.66% +4.31%
Since inception 294.83% Currently unavailable Currently unavailable

Top 10 shares for this fund

Share Name Country Value
Gilead Sciences Inc USA 7.33%
Celgene Corp USA 6.90%
Alexion Pharmaceuticals Inc USA 6.80%
Biogen Inc USA 6.21%
Amgen Inc USA 4.65%
Biomarin Pharmaceutical Inc USA 3.41%
Vertex Pharmaceuticals Inc USA 3.15%
Illumina Inc USA 3.06%
Takeda Pharmaceutical Co Ltd JPN 2.88%
Regeneron Pharmaceuticals Inc USA 2.64%

Currently unavailable